US Leadership Summit


Like this article?

Sign up to our free newsletter

Hellman & Friedman’s Cordis acquires Medalliance in $1.135bn deal

Cordis Corp, a portfolio company of private equity firm Hellman and Friedman (H&F), is to acquire MA Med Alliance SA (Medalliance) in a transaction valued at up to $1.135 billion, according to a report by BioWorld. 

Cordis, which was acquired by H&F in August 2021, is to make  an initial $35 million investment and provide an upfront payment of $200 million at closing in 2023.  Achieving regulatory milestones will trigger a $125 million payment and commercial achievements through to 2029 are tied to an additional $775 million.

Cordis, which formerly owned by Johnson & Johnson, is now backed by backed by H&F and global investment firm KKR as well as Ajax Health.

Switzerland-headquartered Medalliance is the developer of the Selution Sustained Limus Release (SLR) sirolimus-eluting balloon, which Cordxis believes fits well with its existing product line.

Like this article? Sign up to our free newsletter




Blackstone Private Equity

Talk to Us

What would you like to talk with us about? *